drugset / Trial / NCT02463591
Reversal of Dabigatran With Prothrombin Complex Concentrate
Phase 2
Unknown
12 enrolled
University Medical Center Groningen
Boehringer Ingelheim · collabCSL Behring · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to investigate whether Prothrombin Complex Concentrate (PCC) is effective in reversing the anticoagulant effect of Dabigatran, as assessed by two modified skin-bleeding tests.
Timeline
- Start
- 2015-01
- Primary completion
- 2016-07
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prothrombin Complex Concentrate | Protein / enzyme biologic | 50 iu/kg | Intravenous |
Indications
No indication recorded.